Last reviewed · How we verify
NCT04918862
A COMPARATIVE STUDY BETWEEN 1MG AND 3 MG OF GRANISETRON IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN STRABISMUS OPHTHALMIC SURGERIES DURING GENERAL ANESTHESIA
Phase 3 trial testing Granisetron in 1mg Vs 3 mg of Granisetron in 210 participants. Completed in 18 May 2021.
9 May 2021
Quick facts
| Lead sponsor | Cairo University |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 210 |
| Start date | 8 January 2021 |
| Primary completion | 9 May 2021 |
| Estimated completion | 18 May 2021 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Granisetron — full drug profile →
Conditions studied
- 1mg Vs 3 mg of Granisetron — all drugs for 1mg Vs 3 mg of Granisetron →
Sponsor
Cairo University
Who can join
Adults 18 to 60, any sex, with 1mg Vs 3 mg of Granisetron. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigators aim to determine the optimal dose of granisetron in strabismus ophthalmic surgeries under general anesthesia to prevent postoperative nausea and vomiting
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04918862
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Granisetron
Trials testing the same drug.
- NCT06762860 — Intravenous Granisetron Vs Dexmedetomidine on Postspinal in the Cesarean Section. · NA · unknown
- NCT05632224 — Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery · Phase 4 · unknown
- NCT05087615 — Effects of Ondansetron, Metoclopramide and Granisetron on Perioperative Nausea and Vomiting in Patients Undergone Bariat · Phase 3 · completed
- NCT03817970 — Cisplatin Disposition and Kidney Injury · Phase 3 · active not recruiting
- NCT04501211 — Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis · Phase 2 · withdrawn
Other Cairo University trials
Trials by the same sponsor.
- NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
- NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
- NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
- NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
- NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04918862 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cairo University
- Last refreshed: 21 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04918862.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing